神经内窥镜手术的功效和安全性大脑出血 (NESICH 2)
神经内镜手术对大型脑内出血的功效和安全性:多中心,随机,受控的临床试验
This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.
研究概览
详细说明
Previous retrospective studies have demonstrated that neuroendoscopic surgery, compared to conventional craniotomy, significantly reduces operative duration and intraoperative blood loss, enhances hematoma evacuation rates, and improves postoperative outcomes, including neurological recovery, activities of daily living, and quality of life in patients with large cerebral hemorrhage. However, there is a paucity of prospective randomized controlled trials evaluating the efficacy of different surgical techniques for intracerebral hemorrhage. To address this gap, the investigators propose a multicenter, randomized, controlled clinical trial to compare the safety and efficacy of neuroendoscopic surgery versus craniotomy, aiming to provide evidence-based guidance for surgical decision-making in cerebral hemorrhage management.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Rong Hu, MD
- 电话号码:8615123917123
- 邮箱:huchrong@aliyun.com
研究联系人备份
- 姓名:Hua Feng, MD
- 电话号码:8613708321681
- 邮箱:fenghua201818@aliyun.com
学习地点
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400038
- 招聘中
- Southwest Hospital
-
接触:
- Rong Hu, MD
- 电话号码:8615123917123
- 邮箱:huchrong@aliyun.com
-
-
Gansu
-
Wuwei、Gansu、中国、733000
- 招聘中
- Wuwei People's Hospital
-
接触:
- Lishan Ma, MD
- 电话号码:8613639350777
- 邮箱:779795352@qq.com
-
-
Guangxi
-
Wuzhou、Guangxi、中国、543001
- 招聘中
- Wuzhou Workers' Hospital
-
接触:
- Zhongyong Deng, MD
- 电话号码:8613878401206
- 邮箱:gxwzsgryydeng@163.com
-
-
Jilin
-
Siping、Jilin、中国、136000
- 招聘中
- Siping Central People's Hospital
-
接触:
- Xiaodong Li, MD
- 电话号码:8613843436488
- 邮箱:spszxyysjwk@sina.com
-
-
Sichuan
-
Dazhou、Sichuan、中国、635100
- 招聘中
- Dazhu County People's Hospital
-
接触:
- Sheng Zhu, MD
- 电话号码:+8615882911301
- 邮箱:371773434@qq.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18-80 years old, male or female;
- The time between onset and admission to the first diagnostic CT is within 24 hours (for no bystanders and the time of onset is unknown, the time of the last known patient in good condition is used);
- Patients with supratentorial intracerebral hemorrhage who have obvious space-occupying effect caused by hematoma (midline structure shift > 6mm) or hematoma volume ≥ 45ml and require emergency surgery (including patients with signs of cerebral herniation such as decreased or dilated pupillary light reflex on one side);
- Before randomization, GCS score was 5-14, NIHSS score was ≥6;
- mRS Before onset: 0-1 score;
- Randomization within 24 hours after the first diagnostic CT;
- The patient or family members are informed and voluntarily sign the informed consent;
Exclusion Criteria:
- The clinical diagnosis is caused by cerebral aneurysm, cerebrovascular malformation, moyamoya disease, brain trauma, brain tumor, massive cerebral infarction hemorrhage transformation, coagulation dysfunction, etc.;
- Thalamic hemorrhage, primary ventricular hemorrhage;
- Platelet count <75×109/L, INR > 1.4;
- Patients with advanced cerebral hernia (such as dilated bifidus and no light reflex) or unstable vital signs cannot tolerate surgery;
- Irreversible brain stem impairment (eye fixation, bilateral pupil dilation), GCS≤4 points;
- Any history of parenchyma or other intracranial subarachnoid, subdural or epidural blood and surgical history in the past 30 days;
- Patients with severe advanced cognitive impairment (such as AD) or who are not expected to complete the follow-up plan as required;
- Complicated with other serious diseases: including respiratory, circulation, digestion, urinary, endocrine, immune and blood systems;
- Pregnant or breastfeeding women, or those who expect to become pregnant within one year;
- are participating in other clinical trials (excluding: observational studies that do not involve intervention, natural history and/or epidemiological studies).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental Arm
Neuroendoscopic Surgery to remove intracranial hematoma |
Subjects will receive Neuroendoscopic Surgery followed by standard medical management |
|
有源比较器:Control Arm
Craniotomy to remove intracranial hematoma |
Subjects will receive Craniotomy followed by standard medical management |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
大体时间:180 days
|
Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
180 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Length of ICU
大体时间:Number of days from admission, up to 180 days
|
Duration of stay in the ICU |
Number of days from admission, up to 180 days
|
|
Length of hospitalization
大体时间:Number of days from admission to discharge, up to 180 days
|
Duration of stay in the hospital |
Number of days from admission to discharge, up to 180 days
|
|
mRS Shift Analysis of Neurological Improvement Between the Two Groups
大体时间:180 days
|
The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
180 days
|
|
mortality
大体时间:30 days, 90 days and 180 days
|
All cause mortality from onset to 180 days |
30 days, 90 days and 180 days
|
|
Assessment of cognitive function with Mini-Mental State Examination (MMSE)
大体时间:90 days and 180 days
|
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. |
90 days and 180 days
|
|
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
大体时间:30 days and 90 days
|
Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
30 days and 90 days
|
|
Operation duration
大体时间:From the beginning to the end of the surgery
|
The length of the operation |
From the beginning to the end of the surgery
|
|
Peroperative bleeding
大体时间:During surgery
|
The amount of blood lost during surgery |
During surgery
|
|
Intraoperative blood transfusion volume
大体时间:During surgery
|
Intraoperative blood transfusion volume |
During surgery
|
|
Incidence of rebleeding and infection
大体时间:3 days, 7 days, and 30 days after randomization
|
Incidence of rebleeding and infection in the two groups within 3 days, 7 days, and 30 days after randomization |
3 days, 7 days, and 30 days after randomization
|
|
Incidence of complications
大体时间:180 days
|
Incidence of other common complications within 180 days (epilepsy, hydrocephalus, pneumonia, gastrointestinal bleeding, deep vein thrombosis, cardiovascular and cerebrovascular events, etc.) |
180 days
|
|
Incidence of adverse events and serious adverse events
大体时间:180 days
|
Incidence of adverse events and serious adverse events in the two groups within 180 days |
180 days
|
合作者和调查者
调查人员
- 学习椅:Rong Hu, MD、PLA Army Medical University
出版物和有用的链接
一般刊物
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010 Feb;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0. Epub 2010 Jan 5.
- Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005 Jan 29-Feb 4;365(9457):387-97. doi: 10.1016/S0140-6736(05)17826-X.
- Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032-60. doi: 10.1161/STR.0000000000000069. Epub 2015 May 28.
- Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC 3rd, Johnson R, Keigher KM, Mack WJ, Mocco J, Newton EJ, Ruff IM, Sansing LH, Schulman S, Selim MH, Sheth KN, Sprigg N, Sunnerhagen KS; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi: 10.1161/STR.0000000000000407. Epub 2022 May 17. No abstract available.
- Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Munoz-Venturelli P, de Silva A, Thang NH, Wahab KW, Pandian JD, Wasay M, Pontes-Neto OM, Abanto C, Arauz A, Shi H, Tang G, Zhu S, She X, Liu L, Sakamoto Y, You S, Han Q, Crutzen B, Cheung E, Li Y, Wang X, Chen C, Liu F, Zhao Y, Li H, Liu Y, Jiang Y, Chen L, Wu B, Liu M, Xu J, You C, Anderson CS; INTERACT3 Investigators. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023 Jul 1;402(10395):27-40. doi: 10.1016/S0140-6736(23)00806-1. Epub 2023 May 25.
- Pradilla G, Ratcliff JJ, Hall AJ, Saville BR, Allen JW, Paulon G, McGlothlin A, Lewis RJ, Fitzgerald M, Caveney AF, Li XT, Bain M, Gomes J, Jankowitz B, Zenonos G, Molyneaux BJ, Davies J, Siddiqui A, Chicoine MR, Keyrouz SG, Grossberg JA, Shah MV, Singh R, Bohnstedt BN, Frankel M, Wright DW, Barrow DL; ENRICH trial investigators; ENRICH Trial Investigators. Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage. N Engl J Med. 2024 Apr 11;390(14):1277-1289. doi: 10.1056/NEJMoa2308440.
- Beck J, Fung C, Strbian D, Butikofer L, Z'Graggen WJ, Lang MF, Beyeler S, Gralla J, Ringel F, Schaller K, Plesnila N, Arnold M, Hacke W, Juni P, Mendelow AD, Stapf C, Al-Shahi Salman R, Bressan J, Lerch S, Hakim A, Martinez-Majander N, Piippo-Karjalainen A, Vajkoczy P, Wolf S, Schubert GA, Hollig A, Veldeman M, Roelz R, Gruber A, Rauch P, Mielke D, Rohde V, Kerz T, Uhl E, Thanasi E, Huttner HB, Kallmunzer B, Jaap Kappelle L, Deinsberger W, Roth C, Lemmens R, Leppert J, Sanmillan JL, Coutinho JM, Hackenberg KAM, Reimann G, Mazighi M, Bassetti CLA, Mattle HP, Raabe A, Fischer U; SWITCH study investigators. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial. Lancet. 2024 Jun 1;403(10442):2395-2404. doi: 10.1016/S0140-6736(24)00702-5. Epub 2024 May 15.
- Correction to: ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for Brain Hemorrhage: A Multicenter Randomized Controlled Trial. Stroke. 2017 Nov;48(11):e335. doi: 10.1161/STR.0000000000000153. No abstract available.
- Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo SW, Bistran-Hall AJ, Gandhi D, Mould WA, Ullman N, Ali H, Carhuapoma JR, Kase CS, Lees KR, Dawson J, Wilson A, Betz JF, Sugar EA, Hao Y, Avadhani R, Caron JL, Harrigan MR, Carlson AP, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine MR, Patel H, Dodd R, Camarata PJ, Wolfe S, Stadnik A, Money PL, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum JS, Wang W, Anderson CS, Mendelow AD, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad IA; MISTIE III Investigators. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019 Mar 9;393(10175):1021-1032. doi: 10.1016/S0140-6736(19)30195-3. Epub 2019 Feb 7.
- Teo KC, Fong SM, Leung WCY, Leung IYH, Wong YK, Choi OMY, Yam KK, Lo RCN, Cheung RTF, Ho SL, Tsang ACO, Leung GKK, Chan KH, Lau KK. Location-Specific Hematoma Volume Cutoff and Clinical Outcomes in Intracerebral Hemorrhage. Stroke. 2023 Jun;54(6):1548-1557. doi: 10.1161/STROKEAHA.122.041246. Epub 2023 May 22.
- Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993 Jul;24(7):987-93. doi: 10.1161/01.str.24.7.987.
- Sondag L, Schreuder FHBM, Boogaarts HD, Rovers MM, Vandertop WP, Dammers R, Klijn CJM; Dutch ICH Surgery Trial Study Group, part of the CONTRAST consortiumdagger. Neurosurgical Intervention for Supratentorial Intracerebral Hemorrhage. Ann Neurol. 2020 Aug;88(2):239-250. doi: 10.1002/ana.25732. Epub 2020 Apr 30.
- Pinho J, Costa AS, Araujo JM, Amorim JM, Ferreira C. Intracerebral hemorrhage outcome: A comprehensive update. J Neurol Sci. 2019 Mar 15;398:54-66. doi: 10.1016/j.jns.2019.01.013. Epub 2019 Jan 14.
- GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):439-458. doi: 10.1016/S1474-4422(19)30034-1. Epub 2019 Mar 11.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.